Cyclopentane derivatives

Abstract

Compounds of the formula: ##STR1## wherein the two side chains are attached to the ring carbon atoms in the trans configuration, have pharmacological properties typical of prostaglandins, and are especially useful for the treatment of gastric ulceration and gastric hyperacidity.

We claim: 
     
       1. A compound of the formula: ##STR7## wherein the two side chains are attached to the ring carbon atoms in the trans configuration. 
     
     
       2. A compound according to claim 1 which is (±)-2-hydroxymethyl-16-phenoxy-15-oxo-13,14-dihydro-2-decarboxy-11,15-dideoxy-17,18,19,20-tetranorprostaglandin E 1 . 
     
     
       3. A pharmaceutical composition useful in the treatment or prevention of gastric ulceration and gastric hyperacidity which comprises, as active ingredient, an effective amount of a compound of the formula depicted in claim 1 together with a pharmaceutical carrier. 
     
     
       4. A method for the treatment or prevention of gastric ulceration and gastric hyperacidity in a patient which comprises administering to the patient an effective amount of a compound of the formula depicted in claim 1. 
     
     
       5. A method according to claim 4 for the treatment of adult patients with gastric ulceration and of adult patients with gastric hyperacidity in which oral doses of between 0.001 and 0.05 mg/kg body weight of a compound of the formula depicted in claim 1 in the form of a liquid pharmaceutically-acceptable composition, or of between 0.001 and 0.02 mg/kg body weight of a compound of the formula depicted in claim 1 in the form of capsules of absorbable material, is administered two, three of four times per day to the patient. 
     
     
       6. A method according to claim 4 or 5 in which the amount of the compound of the formula depicted in claim 1 administered orally to the patient is 0.01 mg/kg body weight in liquid pharmaceutically-acceptable compositions or 0.02 mg/kg body weight in capsules of absorbable material.